Meda AB completed acquisition of product portfolio from Roche
Lenz & Staehelin advised the Swedish pharma company Meda AB in its acquisition of a product portfolio from Roche for approximately CHF 195 million. The asset purchase transaction included intellectual property rights in four well-established products and related world-wide marketing and distribution rights. Meda is a leading international specialty pharma company listed on the OMX Nordic Stock Exchange.
Lenz & Staehelin's team was led by Matthias Wolf and included Margot Van't dack (Corporate) and Stephan Winkler (Intellectual Property).